

### Attachment A3: Electronic Agent Accountability Record Form

Form Approved: OMB No: 0925-0613 Expires: 03/31/2022

Collection of this information is authorized under 21.CRF.312.57. This information is collected to ensure compliance with Food and Drug Administration (FDA) requirements for NCI as an IND sponsor and that investigational agents are under the control and accounted for by competent authority. The information may be disclosed to researchers for investigational purposes, sponsors of clinical trials and their company collaborators, the applicable Institutional Review Board, NCI, FDA, and Department of Health and Human Services. Submission of this information is voluntary, however, in order for you to conduct a study in accordance with relevant, current protocols, you must complete all fields.

Public reporting burden for this collection of information is estimated to average 1 minute per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to NIH Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN PRA (0925-0613). Do not return the completed form to this address.

## AURORA

[Link to OMB Burden Statement](#)



▲ DARF Information (NCI Supplied) **C-PA015-NRG-GY009-003** [Manage Satellite](#)

**Institution:** University of Pittsburgh Cancer Institute (UPCI) (PA015)     **Investigator:** Olawaiye, Alexander (42476)     [Linked eDARFs](#)

**Shipping Address:** 5110 Centre Avenue, Ground Floor AG40.3, Pittsburgh PA 15232, USA

**Protocol Title:** A Randomized, Phase II/III Study of Pegylated...     **Protocol:** NRG-GY009 (Active)

**Agent:** Atezolizumab (MPDL3280A) (NSC-783608)     **Dose Form & Strength:** 1200 mg Injection     **Bottle Size:** 20 mL Vial

**Dispensing Area:** Oncology Pharmacy [Manage Dispensing Area](#)

**Starting Page No:** 1

▼ Lot Information 3

▲ Completed Transactions 4

Line No	Date	Type	Transaction	Patient Initials	Patient ID	Dose & Schedule	Quantity	Balance	Lot No	Use By Date	Recorder
1	01-Dec-2020	Received from NCI	2020280-0082				+6 (vial)	6 (vial)	Mnfr: HLA Lot: 1160608		Everett, Brad
2	01-Dec-2020	Local Destruction	R20336-0001				-1 (vial)	5 (vial)	Mnfr: HLA Lot: 1160608		Brady Everett